AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026250285
Cite this article
4
Download
60
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Systemic inflammation and risk stratification in pheochromocytoma: Insights from PASS components, TNM stage, and the tumor immune microenvironment

Ümit Çavdar1* Tuğçe Tekinaslan1 Özlem Eren1 Emine Özlem Gür2 Serkan Karaıslı2 Mehmet Haciyanli2 Selda Gücek Haciyanli2 Aslı Kahraman3 Mehmet Sercan Ertürk1 Barış Önder Pamuk1 Serkan Yener4
Show Less
1 Department of Endocrinology and Metabolism, Faculty of Medicine, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir , Turkey
2 Department of General Surgery, Faculty of Medicine, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir , Turkey
3 Department of Pathology, Faculty of Medicine, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir , Turkey
4 Department of Endocrinology and Metabolism, Faculty of Medicine, University of Dokuz Eylül, Izmir , Turkey
Received: 17 June 2026 | Revised: 29 July 2026 | Accepted: 18 August 2026 | Published online: 27 August 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and Tumor–Node–Metastasis (TNM) staging capture histopathological and anatomical risk features in adrenal pheochromocytoma, but do not incorporate systemic inflammation.

Objectives: To investigate the associations of preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with individual PASS components and American Joint Committee on Cancer TNM stage in adrenal pheochromocytoma.

Methods: We retrospectively screened 62 patients; after predefined exclusions, 55 patients with adrenal pheochromocytoma were included. Clinical characteristics, tumor size, urinary metanephrine and normetanephrine levels, PASS components, TNM stage, and preoperative blood counts were recorded. Associations of NLR and PLR with PASS components were assessed using univariate logistic regression, with Benjamini–Hochberg correction across the 12 component-level analyses. NLR and PLR were also compared between Stage I/II and Stage III/IV disease.

Results: After Benjamini–Hochberg correction, associations of NLR with vascular invasion and high cellularity were attenuated, whereas those with capsular invasion, large nests or diffuse growth, tumor necrosis, atypical mitosis, and mitotic activity > 3/10 high-power fields remained significant. NLR was higher in Stage III/IV than Stage I/II disease (median: 3.85; range: 2.17–6.73 vs. median: 2.59; range: 1.52–5.48, p = 0.019). PLR was associated with PASS ≥ 6 in the unadjusted analysis but not with individual PASS components and did not differ by stage.

Conclusion: Higher preoperative NLR was associated with selected PASS components and Stage III/IV disease in adrenal pheochromocytoma. These exploratory findings require validation in larger multicenter cohorts and should not be interpreted as evidence of independent prognostic value.

Keywords
Pheochromocytoma
Paraganglioma
Tumor microenvironment
Neutrophil-to-lymphocyte ratio
Platelet-to-lymphocyte ratio
Pheochromocytoma of the Adrenal Gland Scaled Score
Tumor–Node–Metastasis classification
Funding
None.
Conflict of interest
The authors declare they have no competing interests.
References
  1. Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90-114. doi: 10.1007/s12022-022-09704-6
  2. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic Markers in Pheochromocytoma. Hum Pathol. 1998;29(5):522-526. doi: 10.1016/S0046-8177(98)90070-3
  3. Medley IL, Keiser HR, Steinberg SM, Lack EE. Histopathology of Benign Versus Malignant Sympathoadrenal Paragangliomas: Clinicopathologic Study of 120 Cases Including Unusual Histologic Features. Hum Pathol. 1990;21(11):1168-1180. doi: 10.1016/0046-8177(90)90155-X 
  4. Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23(10):1995-2019. doi: 10.1007/s12094-021-02622-9
  5. Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019;474(6):721-734. doi: 10.1007/s00428-019-02553-5
  6. Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405-414. doi: 10.1530/ERC-13-0494
  7. Wu D, Tischler AS, Lloyd RV, et al. Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009;33(4):599-608. doi: 10.1097/PAS.0b013e318190d3e8
  8. Wachtel H, Hutchens T, Baraban E, et al. Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab. 2020;105(12):e4661-e4670. doi: 10.1210/clinem/dgaa608
  9. de Bresser CJM, de Krijger RR. The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease. Endocr Pathol. 2024;35(4):279-292. doi: 10.1007/s12022-024-09830-3
  10. Jimenez C, Ma J, Gonzalez AR, et al. TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023;108(5):1132-1142. doi: 10.1210/clinem/dgac677
  11. Milinkovic M, Soldatovic I, Zivaljevic V, et al. Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma. Diagnostics. 2024;14(8):849. doi: 10.3390/diagnostics14080849
  12. Ruf B, Greten TF, Korangy F. Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity. Nat Rev Cancer. 2023;23(6):351-371. doi: 10.1038/s41568-023-00562-w
  13. Martinelli S, Amore F, Canu L, Maggi M, Rapizzi E. Tumour microenvironment in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2023;14:1137456. doi: 10.3389/fendo.2023.1137456
  14. Beis D, Von Känel R, Heimgartner N, et al. The Role of Norepinephrine and α-Adrenergic Receptors in Acute Stress-Induced Changes in Granulocytes and Monocytes. Psychosom Med. 2018;80(7):649-658. doi: 10.1097/PSY.0000000000000620
  15. Zhong X, Su TW, Yang Y, et al. Platelet-Lymphocyte and Neutrophil-Lymphocyte Ratios Are Prognostic Markers for Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab. 2023;108(9):2230-2239. doi: 10.1210/clinem/dgad149
  16. Çavdar Ü, Kalender DSY, Yüksel BD, et al. Prognostic Significance of Preoperative NLR or PLR and PASS Score Combinations in Pheochromocytoma and Paraganglioma. Clin Endocrinol (Oxf). 2025;102(3):362-368. doi: 10.1111/cen.15192
  17. Thompson LDR. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases. Am J Surg Pathol. 2002;26(5):551-566. doi: 10.1097/00000478-200205000-00002
  18. Thompson LDR, Gill AJ, Asa SL, et al. Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110:83-97. doi: 10.1016/j.humpath.2020.04.012
  19. Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023
  20. Marques P, De Vries F, Dekkers OM, Korbonits M, Biermasz NR, Pereira AM. Serum Inflammation-based Scores in Endocrine Tumors. J Clin Endocrinol Metab. 2021;106(10):e3796-e3819. doi: 10.1210/clinem/dgab238
  21. Carrión-Barberà I, Lood C. Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers. Front Oncol. 2025;15:1616477. doi: 10.3389/fonc.2025.1616477
  22. Tufton N, Hearnden RJ, Berney DM, et al. The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. Endocr Relat Cancer. 2022;29(11):589-598. doi: 10.1530/ERC-22-0020
  23. Uher O, Vanova KH, Taïeb D, et al. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives. Endocr Rev. 2024;45(4):521-552. doi: 10.1210/endrev/bnae005
  24. Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM, et al. Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun. 2023;14(1):1122. doi: 10.1038/s41467-023-36769-6
  25. Stenman A, Zedenius J, Juhlin CC. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up. Surgery. 2019;166(5):901-906. doi: 10.1016/j.surg.2019.04.030
  26. Abdel-Rahman O. Assessment of the AJCC staging system of pheochromocytomas/paragangliomas. Endocrine. 2022;75(1):239-243. doi: 10.1007/s12020-021-02854-3
  27. Torresan F, Beber A, Schiavone D, et al. Long-Term Outcomes after Surgery for Pheochromocytoma and Sympathetic Paraganglioma. Cancers (Basel). 2023;15(11):2890. doi: 10.3390/cancers15112890
  28. Platini H, Ferdinand E, Kohar K, et al. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2022;58(8):1069. doi: 10.3390/medicina58081069
  29. Guo W, Lu X, Liu Q, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135-4148. doi: 10.1002/cam4.2281
  30. Shi M, Zhao W, Zhou F, et al. Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2020;9(1):45-54. doi: 10.21037/tlcr.2020.01.17
  31. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. doi: 10.3322/caac.21388
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing